Impact of elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy on rates of endoscopic sinus surgery in cystic fibrosis
International Forum of Allergy & Rhinology · 2024
DOI: 10.1002/alr.23400 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Graham Pingree und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Indoles, Cystic Fibrosis Transmembrane Conductance Regulator, Benzodioxoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Elexacaftor/tezacaftor/ivacaftor (ETI), a combination cystic fibrosis transmembrane receptor (CFTR) modulator, has demonstrated improved pulmonary outcomes in individuals with cystic fibrosis (CF). However, ETI's impact on functional endoscopic sinus surgery (FESS) remains unclear.
Methods
The TriNetX Analytics Research Network, consisting of 120 million global de‐identified electronic medical records, was queried from 2012 to 2023 for subjects with CF who underwent sinus surgery. 1 Patients on ETI prior to FESS ( n = 6,056) were propensity score matched to control individuals with CF not on CFTR modulators ( n = 37,906) and those on other FDA‐approved CFTR modulators (tezacaftor/ivacaftor, lumacaftor/ivacaftor, and ivacaftor) ( n = 2437) based on relevant factors. The primary outcome was the absolute risk reduction (ARR) of undergoing FESS. Secondary outcomes included ARR of CF‐related pulmonary exacerbations and hospital admission from 0 to 6, 6 to 12, and 12 to 24 months following FESS.
Results
ETI use demonstrated a significant ARR for FESS when compared to CF patients not on CFTR modulators (2.12%; 95% confidence interval [CI] 1.5–2.75; p ‐value < 0.0001) and those on other CFTR modulators (4.7%; 95% CI 3.54–5.85; p ‐value < 0.0001). No significant differences occurred in secondary outcomes between ETI and non‐CFTR modulator groups, except for reduced CF‐related pulmonary exacerbations from 0 to 6 months post‐FESS. Additionally, a significant reduction in pulmonary exacerbations was observed at all time points and hospital admissions within 6 months following FESS compared to those using other CFTR modulators.
Conclusions
In a large dataset, CF patients on ETI demonstrated significantly reduced risk of FESS, pulmonary exacerbations, and hospital admission compared to patients not on CFTR modulators or those on other CFTR modulators, suggesting improved sinonasal disease and overall health status in CF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
- Department of Otolaryngology-Head and Neck Surgery, Virginia Commonwealth University, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
ORCID-Profile: Graham Pingree, Theodore Schuman
Zitieren
APA
Pingree, G., Bentan, M., Fitzpatrick, T., & Schuman, T. (2024). Impact of elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy on rates of endoscopic sinus surgery in cystic fibrosis. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23400
Vancouver
Pingree G, Bentan M, Fitzpatrick T, Schuman T. Impact of elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy on rates of endoscopic sinus surgery in cystic fibrosis. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23400
BibTeX
@article{Pingree2024,
author = {Pingree, Graham and Bentan, Mihai and Fitzpatrick, Thomas and Schuman, Theodore},
title = {Impact of elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy on rates of endoscopic sinus surgery in cystic fibrosis},
journal = {International Forum of Allergy & Rhinology},
year = {2024},
doi = {10.1002/alr.23400}
}
EUVIMED